Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621000726853
Ethics application status
Approved
Date submitted
22/01/2021
Date registered
10/06/2021
Date last updated
14/07/2024
Date data sharing statement initially provided
10/06/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
Probucol in Alzheimer's Study 2020 (PIA 2020)
Scientific title
A double-blind, placebo controlled, randomised phase II trial of probucol in Alzheimer’s disease: The impact on cognition
Secondary ID [1] 304093 0
None
Universal Trial Number (UTN)
U1111-1259-0486
Trial acronym
PIA-Study
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer's disease 319276 0
Condition category
Condition code
Neurological 317244 317244 0 0
Alzheimer's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The PIA-Study is a randomised controlled research trial examining whether intervention with Probucol supports cognitive function in AD. Participants are randomly assigned to one of two groups, group 1 (placebo) or group 2 (treatment).
After consenting to participate in the study, screening procedures will occur between Days -56 and -1. All subjects must have measurable mild or moderate Alzheimer’s disease, and accordingly screening procedures will include:
• A positive amyloid biomarker (PET scan) indicative of AD pathology,
• Mini-mental-state examination (MMSE) score of 20 or greater,
• Free and cued selective reminding test (FCSRT) cueing index score of less than or equal to 0.79, OR a free recall of less than or equal to 17.
• Clinical Dementia Rating (CDR) global score of 0.5 or 1.0.

Treatment:
Chemical name: 4,4’-[Propan-2,2-diylbis(sulfandiyl)]bis[2,6-bis(1,1- dimethylethyl) phenol]
The proposed dose of Probucol for this protocol adopts contemporary usage published in contemporary clinical trials at 250 mg twice a day. Probucol will be supplied in a commercially available form known as Lorelco.
Study medication will commence (day 1, week 1) with a single dose escalation design with all participants receiving initially for two-weeks 1 X placebo per day. Unused medication is to be returned at every visit to monitor drug compliance. Thereafter, participants will be randomised into the two groups.
Arm 1 (treatment)
Subjects will be dosed as:
• Week 3: 1 x 250 mg Lorelco™ (or matching placebo) taken in the morning, with food.
• Week 4 – 104: 1 x 250 mg Lorelco™ (or matching placebo) taken in the morning, with food. 1 x 250 mg probucol (or matching placebo) taken in the evening, with food.
Study medication will be dispensed as a 2-week supply for 1 interval (weeks 1 & 2); a 2-week supply for weeks 3 & 4; followed by 2 X 10-week supplies and 6 X 13 week supply dispensed at each visit. Unused medication is to be returned at every visit to monitor drug compliance.
Intervention code [1] 318744 0
Treatment: Drugs
Comparator / control treatment
Placebo composition: opaque capsules with no active ingredients and a filler of microcrystalline cellulose.
Study medication will commence (day 1, week 1) with a single dose escalation design with all participants receiving initially for two-weeks 1 X placebo per day. Unused tablets are to be returned to monitor drug compliance.
Arm 2 (placebo)
Subjects will be dosed as:
• Week 3: 1 x matching placebo taken in the morning, with food.
• Week 4 – 104: 1 x matching placebo taken in the morning, with food. 1 x matching placebo taken in the evening, with food.
Study medication will be dispensed as a 2-week supply for 1 interval (weeks 1 & 2); a 2-week supply for weeks 3 & 4; followed by 2 X 10-week supplies and 6 X 13 week supply dispensed at each visit. Unused tablets are to be returned at every visit to monitor drug compliance.
Control group
Placebo

Outcomes
Primary outcome [1] 325304 0
To evaluate the preliminary efficacy of 2x daily 250 mg Lorelco™ on cognitive performance in Alzheimer’s patients over a 102 week treatment period
Timepoint [1] 325304 0
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) will be completed at baseline (week 3, day 1), Week 26 (6 months), week 52 (1 year), week 78 (18 months), and week 104 (2 years; primary endpoint) from randomisation
Secondary outcome [1] 387460 0
To evaluate cerebral amyloid abundance in the brain of Alzheimer’s Disease patients treated with Lorelco™ over a 102 week treatment period.
Timepoint [1] 387460 0
PET scan; During screening phase (day -56 to day -1), and week 104 (2 years)
Secondary outcome [2] 387461 0
To evaluate the Mesial temporal lobe (hippocampus and entorhinal cortex via Scheltens grading) in Alzheimer’s Disease patients treated with Lorelco™ over a 102 week treatment period.
Timepoint [2] 387461 0
MRI scan: Volumetric isotropic T1 scan During Pre-baseline phase (week 1 to week 3), and week 104 (2 years)
Secondary outcome [3] 390917 0
Activities of daily living will be assessed using the Alzheimer's Disease Co-operative Study Mild Cognitive Impairment Activities of Daily Living scale (ADCS-MCI-ADL24)
Timepoint [3] 390917 0
This will be completed at pre-baseline, week 26 (6 months),and week 104 (2 years)
Secondary outcome [4] 394767 0
Depression, anxiety, and stress will be assessed using Depression Anxiety Stress Scale (DASS-21)
Timepoint [4] 394767 0
This will be completed at pre-baseline, week 26 (6 months), and week 104 (2 years
Secondary outcome [5] 394768 0
To assess the safety and tolerability of Lorelco™ in patients with Alzheimer’s Disease via Incidence, type and severity of adverse events.
All AEs will be coded using the current version of the Medical Dictionary of Regulatory Activities (MedDRA). AE's will be assessed using;
-ECG
-Vital signs
-Laboratory evaluations
-Physical examination
-Neurological examination

Possible/know side effects;
diarrhea/loose stools will be self-repored
nausea/vomiting will be self-reported
rash, pruritus and other skin irritations will be assessed via physical assessment
ventricular arrhythmia (torsades de pointes) and QT prolongation will be assessed by ECG
syncope will be assessed via vital signs and physical assessment
gastrointestinal bleeding will be assessed via physical examination and questions about bowel movements
peripheral neuritis will be assessed via neurological examination
Timepoint [5] 394768 0
Adverse event information is collected at Week 3, Week 4, Week 5, Week 6, Week 15, Week 20, Week 26 (6 months), Week 29, Week 39, Week 47, Week 52 (1 year), Week 55, Week 65, Week 73, Week 78 (18 months), Week 81, Week 91, Week 104 (2 years)
Secondary outcome [6] 396308 0
To evaluate small vessel ischaemic lesion load in the brain of Alzheimer’s Disease patients treated with Lorelco™ over a 102 week treatment period.
Timepoint [6] 396308 0
MRI scan: 3D FLAIR scan During Pre-baseline phase (week 1 to week 3), and week 104 (2 years)
Secondary outcome [7] 396309 0
To evaluate micro bleed load and amyloid angiopathy in the brain of Alzheimer’s Disease patients treated with Lorelco™ over a 102 week treatment period.
Timepoint [7] 396309 0
MRI scan: Susceptibility weighted imaging During Pre-baseline phase (week 1 to week 3), and week 104 (2 years)
Secondary outcome [8] 396311 0
To evaluate the preliminary efficacy of 2x daily 250 mg Lorelco™ on cognitive performance in Alzheimer’s patients over a 102 week treatment period
Timepoint [8] 396311 0
The mini-mental state examination (MMSE) will be completed at screening (day -56 to day -1) and week 104 (2 years)
Secondary outcome [9] 396708 0
To evaluate global cortical atrophy (Pasquier scale) in the brain of Alzheimer’s Disease patients treated with Lorelco™ over a 102 week treatment period.
Timepoint [9] 396708 0
MRI scan: Volumetric isotropic T1 scan During Pre-baseline phase (week 1 to week 3), and week 104 (2 years)
Secondary outcome [10] 396709 0
To evaluate parietal atrophy (Koedam score) in the brain of Alzheimer’s Disease patients treated with Lorelco™ over a 102 week treatment period.
Timepoint [10] 396709 0
MRI scan: Volumetric isotropic T1 scan During Pre-baseline phase (week 1 to week 3), and week 104 (2 years)
Secondary outcome [11] 396710 0
To evaluate inferior lateral ventricle size in the brain of Alzheimer’s Disease patients treated with Lorelco™ over a 102 week treatment period.
Timepoint [11] 396710 0
MRI scan: Volumetric isotropic T1 scan During Pre-baseline phase (week 1 to week 3), and week 104 (2 years)

Eligibility
Key inclusion criteria
18 years of age or older,
A positive amyloid biomarker (PET scan) indicative of AD pathology,
Mini-mental-state examination (MMSE) score of 20 or greater,
Free and cued selective reminding test (FCSRT) cueing index score of less than or equal to 0.79, OR a free recall of less than or equal to 17.
Clinical Dementia Rating (CDR) global score of 0.5 or 1.0.
A study partner (partner/spouse/carer) consents to the minimum requirements:
Study partner will attend at least one screening visit
Study partner will be available via phone or in person to provide information to the study as required
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
A patient who meets any of the following exclusion criteria will not be eligible for inclusion in the study:
1. Recorded number of falls in previous 12 months and during trial. Participants who report multiple falls with potential loss of consciousness will be excluded
2. History of QTc-induced prolongation and willingness to limit use of over-the- counter, or prescription medicines (e.g. anti-histamines) known to prolong QTc interval. Corrected QT interval using Bazett's formula (QTcB) interval > 490 msec for males, or 500 msec for females, as detected by ECG and confirmed by physician. Participants who have a history of QTc-induced prolongation and are unwilling to limit use of medication will be excluded.
3. Evidence of abnormal cardiac function as defined by any of the following:
a. Myocardial infarction within 6 months of Cycle 1, Day 1
b. Symptomatic congestive heart failure (New York Heart Association > Class II)
c. Unstable angina
d. Unstable atrial fibrillation including paroxysmal atrial fibrillation. Medicated, stable atrial fibrillation will be assessed by the study doctor on a case-by-case basis.
e. Frequent multifocal ventricular arrhythmia
4. Unable to swallow oral medications.
5. Gastrointestinal conditions that, in the opinion of the Investigator, could affect the absorption of study drug.
6. Use of any prescription or non-prescription (including herbal) medications, or consumption of foods known to be strong QT prolongation within 7 days prior to the first administration of Lorelco™ and for the duration of the study . These include (but are not limited to):
a. Medications
b. With significant central anticholinergic effects,
c. Sedatives,
d. Antiparkinsonian medications that cannot be stopped prior to study entry,
e. Any investigational treatment for AD
7. ‘Current diagnosis of cancer (within 3 years) and/or undergoing chemotherapy, with exception to cancers of the skin such as basal or squamous cell carcinoma in situ of the skin.
8. Significant head injury within 5 years
9. Electrolyte imbalance (e.g. on high steroids, pituitary tumours, and Addison disease)
10. Hypokalaemia, hypomagnesaemia and hypocalcaemia
11. They have other neurologic or psychiatric diagnosis that in the opinion of the investigator could interfere with cognitive function,
12. Major surgery is planned during the conduct of the trial, or a clinical event has occurred in the six months preceding study inclusion that may compromise ability to participate for the duration of the study,
13. Evidence of stroke where the clinical effects are clearly temporally related to the onset of cognitive impairment.
14. Current diagnosis with a psychiatric disorder, or taking psychotropic medications,
15. Other excluded medications will be those that are;
• Specifically contraindicated with Probucol, based on historic clinical indications for the treatment of cardiovascular disease. Stable use (for at least 3 months) of cholinesterase inhibitors and memantine will be allowed.
• Patients on high dose loop-diuretics or thiazide diuretic medications, will be excluded if taking maximum dose of furosemide or Bendroflumethiazide
16. Self-reported human immunodeficiency virus (HIV-1 or HIV-2), hepatitis B (HBsAg) or hepatitis C virus (HCV).
17. Any inflammatory or chronic pain condition that necessitates regular use of opiates/opioids,
18. Major surgery within 28 days of Cycle 1, Day 1, or minor surgical procedures within 7 days of Cycle 1, Day 1. Exception: no waiting period applies following port-a-cath placement for venous access.
19. For women of childbearing potential, a positive pregnancy test at screening, or on Day 1, prior to dose administration.
20. Pregnant or breast-feeding (or planning to breastfeed) while on study through 15 days after the last dose of study drug.
21. Hypersensitivity or other clinically significant reaction to the study drug or its inactive ingredients.
22. Known substance abuse or medical, psychological, or social conditions that, in the opinion of the Investigator, may interfere with the patient’s participation in the clinical study or evaluation of the clinical study results.
23. Any other condition or prior therapy that in the opinion of the Investigator would make the patient unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Permuted block randomisation 1:1 will be utilised to randomly allocate participants via their unique ID to the two treatment arms (treatment vs placebo). Participant IDs will be randomised to either group 1 or group 2 via a computer randomiser. Participant IDs will also be randomised. Participant IDs will be stored (de-identified) at a central administration site. Participant IDs and allocated treatment group will be stored with Oxford Compounding. Only Oxford Compounding will have access to which group a participant belongs to, and may be contacted to disclose information in the event of a severe adverse event.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Efficacy
Statistical methods / analysis
In order to ensure that the study has sufficient power to detect differences in both of the primary outcomes, the sample size chosen is the maximum of that calculated for each primary outcome.
The primary analysis was an intention-to-treat analysis and included all randomized participants. Data will be analysed using both Generalised Estimating Equations (GEE) and Bayesian Analysis.
The analysis of primary endpoints will use linear mixed-effects models, with random slopes and intercepts. For the ADAS-Cog, using mixed model analysis published estimates from the ADNI cohort suggest a sample size of 125 AD participants per trial arm (total N = 250) will be required for power at 0.8 to detect a drug effect of 25% over two years and assuming a decline from baseline of 1.10 standardised units on the composite (SD change = 0.83).
For the MRI markers, Ledig et al. reported the sample sizes required for a 25% intervention reduction over two years based on 322 patients with AD (with 117 followed for 24 months) and a reduction of 10.2% (6.2) for hippocampus. Sample size calculations based on hippocampal volume suggest that 93 subjects per treatment arm are required (total N = 186).
Assuming a 20% attrition rate, a sample of 314 subjects will be recruited for the Cognitive study, and 233 subjects will be randomly chosen for the Imaging study.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
12/07/2021
Actual
11/01/2022
Date of last participant enrolment
Anticipated
1/01/2025
Actual
Date of last data collection
Anticipated
1/01/2025
Actual
Sample size
Target
314
Accrual to date
51
Final
Recruitment in Australia
Recruitment state(s)
SA,TAS,WA
Recruitment hospital [1] 26650 0
Curtin Health Innovation Research Institute - Curtin University
Recruitment hospital [2] 26651 0
The Queen Elizabeth Hospital - Woodville
Recruitment hospital [3] 26744 0
Wicking Dementia Research and Education Centre - University of Tasmania - Hobart
Recruitment postcode(s) [1] 42689 0
7000 - Hobart
Recruitment postcode(s) [2] 42690 0
6102 - Curtin University
Recruitment postcode(s) [3] 42691 0
5011 - Woodville

Funding & Sponsors
Funding source category [1] 306878 0
Government body
Name [1] 306878 0
National Health Medicine Research Council
Country [1] 306878 0
Australia
Primary sponsor type
University
Name
Curtin University
Address
Curtin Health Innovation Research Institute
Kent St
Bentley, WA, 6102
Country
Australia
Secondary sponsor category [1] 307432 0
Charities/Societies/Foundations
Name [1] 307432 0
Alzheimer's Research Australia
Address [1] 307432 0
Clinical Trials Division
Suite 17, Hollywood Specialist Centre,
95 Monash Avenue,
Nedlands, WA, 6009
Country [1] 307432 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 307033 0
Bellberry
Ethics committee address [1] 307033 0
Ethics committee country [1] 307033 0
Australia
Date submitted for ethics approval [1] 307033 0
02/10/2020
Approval date [1] 307033 0
04/05/2021
Ethics approval number [1] 307033 0
HREC2019-11-1063

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 105798 0
Prof Roger Clarnette
Address 105798 0
Australian Alzheimer’s Research Foundation
Suite 17, Hollywood Specialist Centre,
95 Monash Avenue,
Nedlands, WA 6009
Country 105798 0
Australia
Phone 105798 0
+61 08 9389 6433
Fax 105798 0
Email 105798 0
[email protected]
Contact person for public queries
Name 105799 0
PIA Study Coordinator
Address 105799 0
Curtin Health Innovation Research Institute
Curtin University, Building 305
Kent St
Bentley, WA, 6102
Country 105799 0
Australia
Phone 105799 0
+61 0468 532 458
Fax 105799 0
Email 105799 0
[email protected]
Contact person for scientific queries
Name 105800 0
John Mamo
Address 105800 0
Curtin Health Innovation Research Institute
Curtin University, Building 305
Kent St
Bentley, WA, 6102
Country 105800 0
Australia
Phone 105800 0
+61 08 9266 7232
Fax 105800 0
Email 105800 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseEfficacy of probucol on cognitive function in Alzheimer's disease: Study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study).2022https://dx.doi.org/10.1136/bmjopen-2021-058826
N.B. These documents automatically identified may not have been verified by the study sponsor.